Subscribe to RSS
Please copy the URL and add it into your RSS Feed Reader.
https://www.thieme-connect.de/rss/thieme/en/10.1055-s-00034925.xml
Download PDF
Hamostaseologie 2002; 22(01): 45-48
DOI: 10.1055/s-0037-1622008
DOI: 10.1055/s-0037-1622008
Original Article
Faktor XIII und Wundheilung
Factor XIII and wound healingFurther Information
Publication History
Publication Date:
29 December 2017 (online)
Zusammenfassung
Neben den Wunden, bei denen sich im Rahmen der gestörten Heilung eine zunehmende Fragilität der Kapillarstrombahn bildet, sind es vor allem die chronischen Wunden im Zusammenhang mit einem langjährigen Diabetes mellitus oder einer chronischvenösen Insuffizienz, oft infolge eines postthrombotischen Syndroms, bei denen die Permeabilitätsstörung im Sinne einer gesteigerten vaskulären Durchlässigkeit eine eigenständige Problematik darstellt, deren Beherrschung von großem therapeutischen Interesse ist. In der jüngsten Vergangenheit hat sich sowohl in klinischen als auch in experimentellen Untersuchungen gezeigt, dass die Plasmatransglutaminase (Faktor XIIIa) hier einen neuen Ansatz bieten könnte.
Summary
In addition to those wounds with increasing fragility of capillaries during impaired healing, there are especially long lasting diabetic wounds or calf ulcerations due to chronic venous insufficiency or postthrombotic syndrome that show a failure of endothelial barrier function with an increased permeability as an important part of its pathophysiological situation. The possibility of controlling this increased permeability is of great therapeutical interest and may give distinct benefit for wound healing. In the close past, clinical as well as experimental studies revealed the plasma transglutaminase (factor XIIIa) as potential new strategy in treatment of increased vascular permeability.
-
Literatur
- 1 Ádány R, Bárdos H, Muszbek L. Factor XIII in tumor matrix formation and remodelling. Blood Coagul Fibrinolysis 1995; 6: 338.
- 2 Ádány R, Kiss A, Muszbek L. Factor XIII: a marker of mono- and megakaryocytopoiesis. Br J Haematol 1987; 67: 167-72.
- 3 Altmeyer P. Der Wundheilungsprozess aus heutiger Sicht. Sedlarik KM, Lippert H. (Hrsg) Wundheilung und Wundauflagen. Stuttgart: Wissenschaftliche Verlagsgesellschaft mbH. 1996: 32-5.
- 4 Benfer J, Struck H. Factor XIII and fracture healing. Europ Surg Res 1977; 9: 217-23.
- 5 Bollinger A, Herrig I, Fischer M, Hoffmann U, Franzeck UK. Intravital capillaroscopy in patients with chronic venous insufficiency and lymphoedema: relevance to Daflon 500 mg. Int J Microcirc Clin Exp 1995; 15 (Suppl 1) 41-4.
- 6 Bruhn HD, Cristhophers E, Pohl J. Einflüsse des Gerinnungs- und Fibrinolysesystems auf den Wundheilungsprozess und die Thrombusorganisation. Verh Dtsch Ges Inn Med 1987; 84: 1345-8.
- 7 Bruhn HD, Zurborn KH. Influences of clotting factors (thrombin, factor XIII) and of fibronectin on the growth of tumor cells and leukemic cells in vitro. Blut 1983; 46: 85-8.
- 8 Bucala R, Tracey KJ, Cerami A. Advanced glycosylation products quench nitric oxide and mediate defective endothelium-dependent vasodilatation in experimental diabetes. J Clin Invest 1991; 87: 432-8.
- 9 Ciano PS, Colvin RB, Dvorak AM, McDonagh J, Dvorak HF. Macrophage migration in fibrin gel matrices. Lab Invest 1986; 54: 62-70.
- 10 Cohen I, Blankenberg TA, Borden D, Kahn DR, Veis A. Factor XIIIa-catalyzed crosslinking of platelet and muscle actin. Regulation by nucleotides. Biochim Biophys Acta 1980; 628: 365-75.
- 11 Constantini V, Zacharski LR, Memoli VA, Kisiel W, Kudryk BJ, Rousseau SM. Fibrinogen deposition without thrombin generation in primary human breast cancer tissue. Cancer Res 1991; 51: 349-53.
- 12 Curtis CG, Brown KL, Credo RB, Domanik RA, Gray A, Stenberg P, Lorand L. Calciumdependent unmasking of active-center cysteine during activation of fibrin stabilizing factor. Biochemistry 1974; 13: 3774-80.
- 13 Dormandy JA. Microcirculation in venous disorders: The role of white blood cells. Int J Microcirc 1995; 15 Suppl 1 3-8.
- 14 Folk JE. Mechanism and basis for specificity of transglutaminase-catalyzed epsilon-(gamma- glutamyl) lysine bond formation. Adv Enzymol 1983; 54: 1-56.
- 15 Grivaux M, Pieron R. Carcinome bronchioloalvéolaire compliquant une sclérodermie généralisée traitée au long cours par le facteur XIII. Rev Pneumol Clin 1987; 43: 102-3.
- 16 Hornyak TJ, Shafer JA. Interactions of factor XIII with fibrin as substrate and cofactor. Biochemistry 1992; 31: 423-9.
- 17 Ichinose A, Davie EW. Primary structure of human coagulation factor XIII. Adv Exp Med Biol 1988; 231: 15-27.
- 18 Janzen RWC, Bauer W, Tilsner V. The spontaneous course of factor XIII following intracranial hemorrhage: relevant for re-bleeding?. J Neurosurg Sci 1982; 26: 135-6.
- 19 Kaczmarek E, Liu Y, Berse B, Chen CS, McDonagh J. Biosynthesis of plasma factor XIII: evidence for transcription and translation in hepatoma cells. Biochim Biophys Acta 1995; 1247: 127-34.
- 20 Kloczko J, Wojtukiewicz M, Bielawiec M, Zarzycka B, Kinalska I. Plasma factor XIII and some other haemostasis parameters in patients with diabetic angiopathy. Acta Haematol 1986; 76: 81-5.
- 21 Kloczko J, Wojtukiewicz M, Bielawiec M, Zuch A. Alterations of haemostasis parameters with special reference to fibrin stabilization, factor XIII and fibronectin in patients with obliterative atherosclerosis. Thromb Res 1988; 51: 575-81.
- 22 Korsgren C, Cohen CM. Organization of the gene for human erythrocyte membrane protein 4.2: structural similarities with the gene for the a subunit of factor XIII. Proc Natl Acad Sci USA 1991; 88: 4840-4.
- 23 Kradin RL, Lynch GW, Kurnick JT, Erikson M, Colvin RB, McDonagh J. Factor XIIIa is synthesized and expressed on the surface of U-937 cells and alveolar macrophages. Blood 1987; 69: 778-85.
- 24 Leu AJ, Yanar A, Pfister G, Geiger M, Franzeck UK, Bollinger A. Microangiopathy in chronic venous insufficiency. Dtsch Med Wochenschr 1991; 116: 447-53.
- 25 McDonagh J. Biochemistry of fibrin-stabilizing factor (XIII). In: McDonagh J, Seitz R, Egbring R. (eds) Factor XIII. Stuttgart: Schattauer Verlag; 1993: 2-8.
- 26 McDonagh J. Biochemistry of factor XIII and fibrin stabilization. Blood Coagul Fibrinolysis 1995; 6: 334.
- 27 Nagy JA, Henriksson P, McDonagh J. Biosynthesis of factor XIII B subunit by human hepatoma cell lines. Blood 1986; 68: 1272-9.
- 28 Nagy JA, Kradin RL, McDonagh J. Biosynthesis of factor XIII A and B subunits. In: Zappia V, Galletti P, Porta R, Wold F. (Hrsg). Post-Translational modification of proteins. New York: Plenum Press; 1988: 29-49.
- 29 Nawroth PP, Lu J, Abel M, Zhang Y, Riedesel FZE, Bierhaus A, Liliensiek B, Vettermann Th, Lin J, Kasperk C, Ziegler R. Endothelzellstimulation durch AGE - Ein In-vitro-Modell diabetischer Spätschäden. In: Hasslacher C, Spanuth E. (Hrsg) Diabetes und Angiopathie. Berlin: Springer-Verlag; 1993: 33-7.
- 30 Nemes Z, Thomazy V. Factor XIIIa and the classic histiocytic markers in malignant fibrous histiocytoma: a comparative immunohistochemical study. Hum Pathol 1988; 19: 822-9.
- 31 Noll T, Wozniak G, McCarson K, Hajimohammad A, Metzner HJ, Inserte J, Kummer W, Hehrlein FW, Piper HM. Effects of factor XIII on endothelial barrier function. J Exp Med 1999; 189: 1373-82.
- 32 Payé M, Lapière CHM. Wundheilung: Der Beitrag des Gerinnungsfaktors XIII. Die gelben Hefte 1986; 26: 128-35.
- 33 Payé M, Lapière CHM. The lack of attachment of transformed embryonic lung epithelial cells to collagen I is corrected by fibronectin and factor XIII. J Cell Sci 1986; 86: 95-107.
- 34 Poon MC, Russell JA, Low S, Sinclair GD, Jones AR, Blashey W, Ruether BA, Hoar DI. Hemopoietic origin of factor XIII A subunits in platelets, monocytes, and plasma. Evidence from bone marrow transplantation studies. J Clin Invest 1989; 84: 787-92.
- 35 Reitz M, Witzke G, Egbring R, Gutjahr P. Coagulation factors and proteinase inhibitors in the plasma of children with acute lymphoblastic leukoses. Klin Wochenschr 1984; 62: 1165-9.
- 36 Sakata Y, Aoki M. Crosslinking of alpha2-plasmin inhibitor to fibrin by fibrin-stabilizing factor. J Clin Invest 1980; 65: 290-7.
- 37 Shainoff JR, Valenzuela R, Urbanic DA, DiBello PM, Lucas FV, Graor R. Fibrinogen A alpha and gamma-chain dimers as potential differential indicators of atherosclerotic and thrombotic vascular disease. Blood Coagul Fibrinolysis 1990; 1: 499-503.
- 38 Toida M, Okumura Y, Swe-Win KK, Oka N, Takami T, Adany R. Characterization of cells containing factor XIII subunit a in benign and malignant buccal lesions. Histochem J 1995; 27: 449-56.
- 39 Turnock K, Bulmer JN, Gray C. Phenotypic characterization of macrophage subpopulations and localization of factor XIII in stromal cells of carcinomas. Histochem J 1990; 22: 661-6.
- 40 Wozniak G, Dapper F, Alemany J. Factor XIII in ulcerative leg disease: background and preliminary clinical results. Semin Thromb Hemost 1996; 22: 445-50.
- 41 Wozniak G, Harbarth P, Segelken K, Alemany J. Der Einfluss des aktuellen Gerinnungsstatus auf das Ergebnis der semilokalen rt-PA-Lyse bei der distalen Zwei-Etagen-Venenthrombose. Hämostaseologie 1995; 15: 225-31.
- 42 Wozniak G, Lutz H, Noll T, Alemany J. Behandlung stark sekretierender, chronischer Wunden mit Faktor XIII: III – Klinische Modalitäten und Ergebnisse. ZfW 2001; 20: 10-3.
- 43 Wozniak G, Montag H, Alemany J. Lokalapplikation von Faktor XIII zur Therapie cruraler Ulcerationen bei Patienten mit postthrombotischer Anamnese: klinische Bewertung einer Pilotuntersuchung. Vasomed 1993; 5: 644-51.
- 44 Wozniak G, Noll T, Bott U, Hehrlein FW. Faktor XIII: experimentelle und klinische Ergebnisse beim diabetischen Malum perforans. Zentralbl Chir 1999; 124 (Suppl 1): 73-7.
- 45 Wozniak G, Noll T, Brunner U, Hehrlein FW. Topical treatment of venous ulcer with fibrin stabilizing factor: experimental investigation of effects on vascular permeability. VASA 1999; 28: 160-3.
- 46 Wozniak G, Noll T, Dapper F, Piper HM, Hehrlein FW. The fibrin-stabilizing factor as a topical means for leg ulcer healing: biochemical and experimental properties and clinical results. Int J Angiol 1998; 7: 109-14.
- 47 Wozniak G, Noll T, Hehrlein FW. Einfluss von Faktor XIII auf die endotheliale Barriere – Klinik und Experiment. In: Egbring R, Seitz R, Wozniak G. (Hrsg). Klinische Aspekte des Faktor-XIII-Mangels Basel: Karger; 1999: 16-25.